Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 4/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16908277 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL71244 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1885718 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL71243 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15508352 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15508459 | 0.85 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL19915056 | 0.80 | CHRM2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL622600 | 0.80 | CHRM2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL220833 | 0.80 | CHRM2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL29102381 | 0.80 | CHRM2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758530-B2 | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160122363-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122363-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2D6, TPMT | CHRM2 2529/4885CHRM1 1693/4885CHRM3 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.